CDK4 and neuroblastoma: Kaplan–Meier survival analyses showed that patients in the high CDK4 expression group exhibited both significantly lower OS (Figure 3B,E) and lower EFS (Figure 3C,F) compared to patients in the low group in both datasets, supporting the potential oncogenic function of CDK4 to promote tumor progression and to drive poorer prognosis in neuroblastoma patients.